In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But ...

Most cell therapies in development use a T cell or some other type of immune cell that’s engineered to perform a particular therapeutic task. Rubius Therapeutics makes its cell therapies from red ...

Rubius Therapeutics, Inc. (RUBY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Cambridge, Massachusetts-based Rubius Therapeutics will spend up to $155 million to renovate a site in Rhode Island into a manufacturing facility for its therapy that will weaponize red blood cells in ...

Rubius Therapeutics shares more than doubled during Monday's session after investors received the biotech firm's outline of results from early-stage tests of a potential cancer drug. The company said ...

Two patients with cancer showed partial tumor shrinkage after infusions of a novel immune-boosting treatment derived from red blood cells, its maker Rubius Therapeutics said Monday. Rubius said the ...

Cell therapy is one of the big ideas in biotech. Entrepreneurs have become captivated by possibilities of engineering white blood cells so they can be re-infused into patients and fight cancer. One ...